Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Changchun High-Tech Industries (000661.SZ) pledged 20.83 million shares by the controlling shareholder.
Changchun High-Tech Industries (000661.SZ) announced that the company recently received a notice from its controlling shareholder, Changchun Chaoda Investment Group Co., Ltd ...
Changchun High-Tech Industries (000661.SZ) terminates the implementation of the 2022 restricted stock and stock option incentive plan.
Changchun High-Tech Industries (000661.SZ) has issued an announcement that the company has approved the "Termination of Implementation of Restriction in 2022..."
Changchun High-tech Industries (000661.SZ): The application for the listing of the controlled subsidiary's restructuring personnel promoting follicle-stimulating hormone-CTP fusion protein injection has been accepted.
On July 18th, Gelunhui reported that Changchun High-tech Industries (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as 'Jinsai Pharmaceutical'), recently received a 'Notice of Acceptance' issued by the National Drug Administration for the approved product - Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection. Infertility is a problem for childbearing couples in various countries and regions worldwide. With the decrease of birth population in recent years and the acceleration of population aging, the country has issued multiple policies to encourage childbirth. The huge population base has led to a huge demand for assisted reproduction technology. Jinsai Pharmaceutical is starting
Changchun High-Tech Industries (000661.SZ) has released its pledge on 5.15% of the company's shares held by its controlling shareholder.
Changchun High-Tech Industries (000661.SZ) announced that the company recently received a notice from its controlling shareholder, Changchun Chaoda Investment Group Co., Ltd ...
As of the end of March 2024, Changchun High-Tech Industries' subsidiary, High-Tech Real Estate, had total assets of 6.083 billion yuan and net assets of 2.471 billion yuan.
Changchun High-tech Industries (000661.SZ) stated on the investor platform that since its inception, the company has successfully transformed from focusing on high-tech zone infrastructure construction to becoming a conglomerate that focuses on pharmaceutical technology innovation and implements industrial investment. As of the end of March 2024, the total assets of the company's subsidiary, High-tech Real Estate, were 6.083 billion yuan, with a net asset of 2.471 billion yuan. Currently, the company actively monitors changes in the real estate industry, continues to focus on sales, strives to clear inventory, and accelerates the return of funds.
Institutions Own 22% of Changchun High-Tech Industry (Group) Co., Ltd. (SZSE:000661) Shares but Retail Investors Control 50% of the Company
Changchun High & New Technology Unit Gets Nod for Progesterone Injection
Changchun High & New Technology Industries' Unit Gets Approval for Protein Detection Kit
Changchun High-tech Industries (000661.SZ): Subsidiary company obtains medical instrument registration certificate.
Changchun High-tech Industries (000661.SZ) announced on June 17 that its subsidiary, Shanghai Sai-Increased Medical Technology Co., Ltd., has received a medical device registration certificate (in vitro diagnostic reagents) issued by the Shanghai Food and Drug Administration. The product name is Insulin-like Growth Factor Binding Protein 3 (IGFBP-3) detection kit (fluorescence immunoassay). The acquisition of the new product medical device registration certificate further enriches the company's product line and will have a positive impact on the company's business development.
Is Changchun High-Tech Industry (Group) (SZSE:000661) A Risky Investment?
Shareholders in Changchun High-Tech Industry (Group) (SZSE:000661) Are in the Red If They Invested Three Years Ago
Changchun High & New Technology's Unit Gets Nod to Trial Jinnazumab Injection
Changchun Hi-Tech (000661.SZ): Jinsai Pharmaceutical's Jinnazumab Injection Approved for Drug Clinical Trials
Gelonghui, May 22丨Changchun Hi-Tech (000661.SZ) announced that recently, Changchun Jinsai Pharmaceutical Co., Ltd. (“Jinsai Pharmaceutical”), a holding subsidiary of Changchun Hi-Tech Industry (Group) Co., Ltd., received a “Drug Clinical Trial Approval Notice” from the State Drug Administration for kinazumab injections. The company's ginnalizumab is a new class 1 drug for therapeutic biological products. It is an anti-IL-1beta antibody drug produced through genetic engineering technology, etc. Previously, the marketing application for injectable kinnamab (anti-IL-1beta antibody) for acute gout arthritis had already been obtained
Changchun Hi-Tech (000661.SZ): The main business is R&D, production and sales of biopharmaceuticals and proprietary Chinese medicines
Gelonghui, May 9丨Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that synthetic biology is an emerging discipline based on engineering design concepts, combining interdisciplinary technologies such as biology, chemistry, medicine, engineering, computer and data science, to transform or create artificial life systems. Currently, the company's main business is R&D, production and sales of biopharmaceuticals and proprietary Chinese medicines. The business segment covers various pharmaceutical segments such as genetic engineering, biological vaccines, antibody drugs, high-end chemicals, modern traditional Chinese medicine, etc. The company will actively pay attention to industry and technological progress, and according to the actual situation and development plans
Investors Don't See Light At End Of Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Tunnel
Changchun Hi-Tech (000661.SZ) subsidiary's application for marketing licensing of Baike Bio's live attenuated nasal spray influenza vaccine was accepted
Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary Changchun Baike Biotechnology Co., Ltd. (abbreviated as “...
Changchun Hi-Tech (000661.SZ): Net profit of 859 million yuan in the first quarter increased 0.20% year-on-year
Gelonghui, April 19 | Changchun Hi-Tech (000661.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 3.177 billion yuan, up 14.39% year on year; net profit attributable to shareholders of listed companies was 859 million yuan, up 0.20% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 847 million yuan, down 0.86% year on year; basic earnings per share were 2.13 yuan.
Changchun Hi-Tech (000661.SZ): Application for marketing of injectable triprorelin acetate microspheres accepted
Gelonghui, April 18 | Changchun Hi-Tech (000661.SZ) announced, Changchun Hi-Tech (000661.SZ) announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's marketing application for injectable triprorelin acetate microspheres was accepted. The company's injectable triprorelin acetate microsphere products improve drug safety by improving drug release characteristics, optimizing prescriptions and processes, and making it possible for pediatric patients to administer fixed doses. A more convenient method of administration supported by evidence-based medical evidence will be central precocious puberty (C
Declining Stock and Solid Fundamentals: Is The Market Wrong About Changchun High-Tech Industries (Group) Inc. (SZSE:000661)?
No Data